Please provide your email address to receive an email when new articles are posted on . Age, nulliparity, polyps and shorter sampling intervals may predict endometrial hyperplasia and cancer. Risk ...

Although it might seem reasonable to pronounce women cured after their endometrial hyperplasia regresses from hormonal treatment, researchers caution that long-term monitoring for relapse and cancer ...

Please provide your email address to receive an email when new articles are posted on . Conjugated estrogen/bazedoxifene users had higher endometrial cancer and endometrial hyperplasia rates vs.

Several studies have investigated the mechanisms involved in progestin resistance. Decreased availability of progestin receptors before treatment or alterations in progestin receptor regulatory ...

Women with atypical endometrial hyperplasia have an increased risk of developing cancer Researchers from the University of Edinburgh have revealed that improved patient care is needed to reduce cancer ...

Endometrial hyperplasia (EH) is a condition in which the uterine lining is thicker than normal. It may have many causes, but the most important association is with endometrial malignancy. For this ...

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 We conducted a case ...

How would you proceed with a 64-year-old woman who has complex endometrial hyperplasia and secretory changes? The patient is not receiving hormone replacement therapy, and her follicle-stimulating ...

Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately 121 out of every ...

Endometrial cancer is one of the few cancers that doesn’t stay quiet. That’s why you should never brush off spotting between periods or any bleeding after menopause. When caught early, this cancer is ...

Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the ...